 HOUSTON, Oct. 19, 2021 PRNewswire -- Moleculin Biotech, Inc., Nasdaq: MBRX Moleculin or the Company, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced it has received authorization from the Medicines and Healthcare Products Regulatory Agency MHRA to commence a Phase 1a clinical trial of WP1122 in the United Kingdom. WP1122, the Companys lead metabolismglycosylation inhibitor, is a prodrug of a well-known antimetabolite called 2-deoxy-D-glucose 2-DG currently being developed for inhibition of viral replication and disease manifestations in humans infected with SARS-CoV-2, the virus responsible for COVID-19. 